Albuminuric vs. non-albuminuric CKD: baseline data from the Progredir cohort study

Abstract

In the last years, albuminuria has emerged as an important biomarker of CKD progression, risk of ESRD, cardiovascular disease and mortality. In the context of proteinuric renal diseases, albuminuria is largely used to assess risk of CKD progression and response to medical treatments. However, it is currently known that in a subgroup of CKD patients, albuminuria does not present a good performance as a biomarker, even in diabetes. The absence of albuminuria in a substantial number of CKD patients offers the opportunity for interesting insights in the pathophysiology of albuminuria, its correlation to histopathological patterns, as well as its use as a biomarker of disease and treatment. The objective of the present study is to evaluate in the baseline data of Progredir Study, a prospective CKD Cohort Study in São Paulo with CKD participants class III and IV, the clinical-laboratorial determinants of albuminuria. Variables that will be assessed include medical history, anthropometry, heart echography, electrocardiogram, vascular calcification (Agatston score), renal function, uremia-related dysfunctions (such as mineral metabolism, anemia and metabolic acidosis), traditional cardiovascular risk factors and insulin resistance. (AU)